Phase I study of 5-FU + Oxaliplatin + Irinotecan + Levofolinate + Panitumumab as the first-line therapy in patients with KRAS or RAS wild-type metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: FOLFOXIRI+Panitumumab (Until 12 courses) Panitumumab 6mg/kg/bi-weekly Irinotecan 165-125mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 3200mg/m2/bi-weekly
Primary outcome(s): Recommended Dose
Study Design: Single arm Non-randomized
DISEASE(S): Kras Or Ras Wild-type Metastatic Colorectal Cancer
PROVIDER: 2630804 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA